FGF-2, or fibroblast growth factor 2, is a key member of the fibroblast growth factor family, renowned for its pivotal role in diverse cellular processes spanning embryonic development to tissue homeostasis in adult organisms. Functionally, FGF-2 operates through binding to specific high-affinity cell surface receptors known as fibroblast growth factor receptors (FGFRs). The activation of FGF-2 signaling pathways commences upon ligand-receptor interaction, where FGF-2 binds to FGFRs, inducing conformational changes that facilitate receptor dimerization and activation of the intracellular tyrosine kinase domains. This activation leads to the phosphorylation of tyrosine residues within the receptors, subsequently triggering downstream signaling cascades pivotal for cellular responses. Among these cascades, the mitogen-activated protein kinase (MAPK) pathway and phosphoinositide 3-kinase (PI3K)/Akt pathway are prominently involved, orchestrating diverse cellular processes such as proliferation, differentiation, migration, and survival.
Activation of FGF-2 signaling pathways is tightly regulated and involves intricate mechanisms that govern ligand-receptor interactions and downstream signaling events. The process initiates with the binding of FGF-2 to FGFRs, a step crucial for receptor activation and subsequent signal transduction. Following ligand-receptor binding, receptor dimerization occurs, facilitating autophosphorylation of tyrosine residues within the intracellular domains of FGFRs. This phosphorylation event serves as a platform for the recruitment and activation of downstream signaling molecules, including adaptor proteins and enzymes such as Ras, Raf, MAPK, and Akt, which propagate the signal to intracellular effectors, ultimately modulating gene expression and cellular responses. Additionally, the activation of FGF-2 signaling can be influenced by various regulatory mechanisms, including post-translational modifications of FGF-2 or FGFRs, as well as interactions with extracellular matrix components and co-receptors. Overall, the activation of FGF-2 signaling pathways is a complex and tightly regulated process essential for orchestrating diverse cellular functions critical for organismal development and tissue homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Heparin | 9005-49-6 | sc-507344 | 25 mg | $119.00 | 1 | |
Heparin, a glycosaminoglycan, directly activates FGF-2 by binding to and stabilizing the FGF-2-FGFR complex. This interaction prolongs FGF-2 signaling, leading to increased cell proliferation and differentiation through pathways such as MAPK and PI3K/Akt. | ||||||
Dovitinib, Free Base | 405169-16-6 | sc-396771 sc-396771A | 10 mg 25 mg | $170.00 $350.00 | ||
Dovitinib, a multi-tyrosine kinase inhibitor, indirectly activates FGF-2 by inhibiting several receptor tyrosine kinases, including FGFRs. Inhibition of FGFRs results in increased FGF-2 expression and signaling, promoting angiogenesis and cell survival through pathways like MAPK and Akt. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Nintedanib, a triple angiokinase inhibitor, indirectly activates FGF-2 by suppressing FGFR signaling through the inhibition of multiple kinases. This leads to increased FGF-2 expression and enhanced activation of downstream pathways, promoting angiogenesis and tissue repair through MAPK and PI3K/Akt signaling. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Suramin, a polysulfonated naphthylurea, directly activates FGF-2 by binding to the FGF-2-FGFR complex and stabilizing receptor interactions. This interaction enhances FGF-2 signaling, contributing to processes such as angiogenesis and tissue repair through pathways like MAPK and PI3K/Akt. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide, an immunomodulatory drug, directly activates FGF-2 by promoting its expression and release. This interaction enhances FGF-2 signaling, contributing to processes such as angiogenesis and tissue repair through pathways like MAPK and PI3K/Akt. | ||||||